ArticleCancer medicine2026
Hepatic-Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi-Omics Analysis of Tumors With Lymphovascular Invasion.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The TITANIA (mulTi omIcs daTa cANcer dIagnostics therApies) study is an international collaboration to generate high-quality multi-omics cancer profiles. We conducted an exploratory investigation within this framework to understand the molecular basis of lymphovascular invasion (LVI), a critical determinant of metastatic potential in clear cell renal cell carcinoma (ccRCC). We analyzed 31 ccRCC specimens (11 LVI+, 20 LVI-) from the National Cancer Center Hospital East using whole-genome sequencing, RNA sequencing, and proteomic profiling. Our findings were integrated with public single-cell RNA sequencing (GSE159115) and spatial transcriptomics (GSE175540) datasets to provide a broader biological context. LVI+ tumors consistently showed a distinctive hepatic-lineage gene expression signature, with significant upregulation of aldolase B (ALDOB) and other liver-specific metabolism genes at both the RNA and protein levels. Single-cell analysis identified a previously unrecognized hepatic-differentiated tumor subpopulation expressing master transcription factors HNF1A and HNF4A, which was positioned at the terminal stages of tumor evolution. Comparison with established hepatocyte gene signatures from three independent databases confirmed enrichment of hepatic metabolic programs in this subpopulation. Spatial transcriptomics revealed preferential localization within hypoxic tumor regions. A metabolic program resembling hepatic lineage differentiation, associated with aggressive disease features including LVI and hypoxic microenvironments, offers preliminary insights into renal cancer progression and potential biomarker development. This is a discovery-based, hypothesis-generating study; all findings require independent functional validation before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.